Literature DB >> 22938201

Rescue of nonsense mutations by amlexanox in human cells.

Sara Gonzalez-Hilarion1, Terence Beghyn, Jieshuang Jia, Nadège Debreuck, Gonzague Berte, Kamel Mamchaoui, Vincent Mouly, Dieter C Gruenert, Benoit Déprez, Fabrice Lejeune.   

Abstract

BACKGROUND: Nonsense mutations are at the origin of many cancers and inherited genetic diseases. The consequence of nonsense mutations is often the absence of mutant gene expression due to the activation of an mRNA surveillance mechanism called nonsense-mediated mRNA decay (NMD). Strategies to rescue the expression of nonsense-containing mRNAs have been developed such as NMD inhibition or nonsense mutation readthrough.
METHODS: Using a dedicated screening system, we sought molecules capable to block NMD. Additionally, 3 cell lines derived from patient cells and harboring a nonsense mutation were used to study the effect of the selected molecule on the level of nonsense-containing mRNAs and the synthesis of proteins from these mutant mRNAs.
RESULTS: We demonstrate here that amlexanox, a drug used for decades, not only induces an increase in nonsense-containing mRNAs amount in treated cells, but also leads to the synthesis of the full-length protein in an efficient manner. We also demonstrated that these full length proteins are functional.
CONCLUSIONS: As a result of this dual activity, amlexanox may be useful as a therapeutic approach for diseases caused by nonsense mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22938201      PMCID: PMC3562214          DOI: 10.1186/1750-1172-7-58

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  48 in total

1.  The major 5' determinant in stop codon read-through involves two adjacent adenines.

Authors:  Sanaa Tork; Isabelle Hatin; Jean-Pierre Rousset; Céline Fabret
Journal:  Nucleic Acids Res       Date:  2004-01-21       Impact factor: 16.971

Review 2.  Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA.

Authors:  Cyril F Bourgeois; Fabrice Lejeune; James Stévenin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2004

3.  Inhibition by amoxanox (AA-673) of the immunologically, leukotriene D4- or platelet-activating factor-stimulated bronchoconstriction in guinea pigs and rats.

Authors:  T Saijo; H Kuriki; Y Ashida; H Makino; Y Maki
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

4.  Impact of the six nucleotides downstream of the stop codon on translation termination.

Authors:  O Namy; I Hatin; J P Rousset
Journal:  EMBO Rep       Date:  2001-08-23       Impact factor: 8.807

5.  The antiallergic agent amoxanox suppresses SRS-A generation by inhibiting lipoxygenase.

Authors:  T Saijo; H Makino; S Tamura; H Kuriki; Y Ashida; S Terao; Y Maki
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

6.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment.

Authors:  L Bidou; I Hatin; N Perez; V Allamand; J-J Panthier; J-P Rousset
Journal:  Gene Ther       Date:  2004-04       Impact factor: 5.250

7.  Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines.

Authors:  J Caamano; B Ruggeri; S Momiki; A Sickler; S Y Zhang; A J Klein-Szanto
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

8.  The pioneer translation initiation complex is functionally distinct from but structurally overlaps with the steady-state translation initiation complex.

Authors:  Shang-Yi Chiu; Fabrice Lejeune; Aparna C Ranganathan; Lynne E Maquat
Journal:  Genes Dev       Date:  2004-04-01       Impact factor: 11.361

9.  Mechanism of the action of amoxanox (AA-673), an orally active antiallergic agent.

Authors:  T Saijo; H Kuriki; Y Ashida; H Makino; Y Maki
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

10.  Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells.

Authors:  A L Cozens; M J Yezzi; L Chin; E M Simon; W E Finkbeiner; J A Wagner; D C Gruenert
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

View more
  71 in total

Review 1.  McArdle disease: a unique study model in sports medicine.

Authors:  Alfredo Santalla; Gisela Nogales-Gadea; Niels Ørtenblad; Astrid Brull; Noemi de Luna; Tomàs Pinós; Alejandro Lucia
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

Review 2.  Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.

Authors:  Akihiro Taguchi; Keisuke Hamada; Yoshio Hayashi
Journal:  J Antibiot (Tokyo)       Date:  2017-09-27       Impact factor: 2.649

3.  Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.

Authors:  Venkateshwar Mutyam; Ming Du; Xiaojiao Xue; Kim M Keeling; E Lucile White; J Robert Bostwick; Lynn Rasmussen; Bo Liu; Marina Mazur; Jeong S Hong; Emily Falk Libby; Feng Liang; Haibo Shang; Martin Mense; Mark J Suto; David M Bedwell; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

4.  Caspases shutdown nonsense-mediated mRNA decay during apoptosis.

Authors:  J Jia; A Furlan; S Gonzalez-Hilarion; C Leroy; D C Gruenert; D Tulasne; F Lejeune
Journal:  Cell Death Differ       Date:  2015-03-06       Impact factor: 15.828

5.  Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins.

Authors:  Jieshuang Jia; Elisabeth Werkmeister; Sara Gonzalez-Hilarion; Catherine Leroy; Dieter C Gruenert; Frank Lafont; David Tulasne; Fabrice Lejeune
Journal:  J Cell Sci       Date:  2017-07-25       Impact factor: 5.285

6.  When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.

Authors:  Moran Shalev; Timor Baasov
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 7.  Viral Evasion and Manipulation of Host RNA Quality Control Pathways.

Authors:  J Robert Hogg
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

8.  Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.

Authors:  Peter M Haggie; Puay-Wah Phuan; Joseph-Anthony Tan; Haijin Xu; Radu G Avramescu; Doranda Perdomo; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Gergely L Lukacs; Alan S Verkman
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

Review 9.  Nonsense-mediated mRNA decay in humans at a glance.

Authors:  Tatsuaki Kurosaki; Lynne E Maquat
Journal:  J Cell Sci       Date:  2016-01-19       Impact factor: 5.285

Review 10.  Therapeutics based on stop codon readthrough.

Authors:  Kim M Keeling; Xiaojiao Xue; Gwen Gunn; David M Bedwell
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-18       Impact factor: 8.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.